Background/aims: This study aims to assess the prognosis of liver transplantation for ICC patients and try to identify prognostic factors that could influence survival for intrahepatic cholangiocarcinoma patients treated by liver transplantation.

Methodology: Between February 1999 and February 2010, 20 patients with ICC underwent liver transplantation. The Kaplan-Meier method was used to calculate the actuarial survival rate and tumor-free survival rate. Log-rank test was used to compare the differences between groups. Univariate Cox proportional hazard regression model was used to analyze each factor that might have influenced liver transplantation prognosis in ICC patients and to identify factors with statistical significance.

Results: Actuarial survival rate at 1, 2, 3 and 5 years achieved 84.2%, 43.7%, 32.7% and 21.8%, respectively. Tumor-free survival at 1, 2, 3 and 5 years was 55.6%, 43.2%, 28.8% and 18.8%, respectively. In univariate analysis, lobar distribution, multiple tumors, lymph node invasion, macrovascular invasion, advanced pTNM classification stages, neoadjuvant therapy and differentiation were associated significantly with survival, especially the former 6 factors. In multivariate analysis, lymph node invasion, macrovascular invasion and multiple tumors were the independent predictors of survival, especially lymph node invasion and multiple tumors.

Conclusion: Liver transplantation in patients with ICC should be confined to highly discreetly selected cases. Consequently, liver transplantation combined with neoadjuvant treatment for these cases may achieve an improved survival.

Download full-text PDF

Source
http://dx.doi.org/10.5754/hge10704DOI Listing

Publication Analysis

Top Keywords

liver transplantation
24
survival rate
12
lymph node
12
node invasion
12
prognostic factors
8
intrahepatic cholangiocarcinoma
8
icc patients
8
patients identify
8
survival
8
patients icc
8

Similar Publications

Background: Mycobacterium avium complex (MAC) is a common pathogen causing non-tuberculous mycobacterial infections, primarily affecting the lungs. Disseminated MAC disease occurs mainly in immunocompromised individuals, such as those with acquired immunodeficiency syndrome, hematological malignancies, or those positive for anti-interferon-γ antibodies. However, its occurrence in solid organ transplant recipients is uncommon.

View Article and Find Full Text PDF

Pifithrin-μ sensitizes mTOR-activated liver cancer to sorafenib treatment.

Cell Death Dis

January 2025

Department of Organ Transplantation and Hepatobiliary Surgery, Key Laboratory of Organ Transplantation of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.

TSC2, a suppressor of mTOR, is inactivated in up to 20% of HBV-associated liver cancer. This subtype of liver cancer is associated with aggressive behavior and early recurrence after hepatectomy. Being the first targeted regimen for advanced liver cancer, sorafenib has limited efficacy in HBV-positive patients.

View Article and Find Full Text PDF

Background: Liver cirrhosis accounts for more than 90 % of portal hypertension cases, and the other cases are due to noncirrhotic portal hypertension (NCPH). Variceal bleeding is the most life-threatening complication of portal hypertension and its primary treatment is medical according to the Baveno VII guidelines. This review discusses the evidence on surgical portal decompression for adult patients with NCPH secondary to chronic extrahepatic portal vein obstruction (EHPVO).

View Article and Find Full Text PDF

Liver transplantation (LT) has an incidence of intraoperative cardiopulmonary arrest (CPA) of around 5%. Patients who experience CPA during this procedure have a reduced survival rate of approximately 50%. Most CPAs occur during the neohepatic phase due to reperfusion syndrome, but this is not always the underlying cause, and a broad differential diagnosis must be performed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!